BioPharmSignal logoBioPharmSignal

Biotech News

Delcath Systems Highlights Clinical Program Presentations at ESMO Congress 2026 and Independent Data on Percutaneous Hepatic Perfusion in Liver-Dominant Metastatic Uveal Melanoma

Delcath Systems (DCTH)Delcath SystemsCompany update

QUEENSBURY, N.Y. --(BUSINESS WIRE)--Oct. 19, 2026-- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced presentations related to its clinical development programs at the European Society

Related news

DCTHDelcath Systems2026-09-11 20:01 EST

Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

DCTHDelcath Systems2026-08-31 20:01 EST

Delcath Systems to Participate in Upcoming Investor Conferences

IDYAIDEAYA Biosciences2026-10-19 10:00 EST

IDEAYA Biosciences and Servier Announce Data From Three Clinical Trials at ESMO 2026 Supporting the Potential of Darovasertib to Become a Foundational New Therapy for Patients Across the Treatment Journey of Uveal Melanoma

IARTIntegra LifeSciences2026-10-16 12:40 EST

Integra LifeSciences to Highlight ENT and Instruments Portfolios and Sponsor New Clinical Research Presentations at AAO-HNSF 2026 Annual Meeting

BNTXBioNTech2026-10-13 10:45 EST

BioNTech Provides Update on Phase 2/3 Clinical Trial for mRNA Cancer Immunotherapy Candidate BNT113 in Metastatic HPV16-positive Head and Neck Cancer

TMCITreace Medical Concepts2026-09-15 21:07 EST

Treace Highlights Product Innovations and Clinical Data Across its Expanding Foot & Ankle Portfolio at the 2026 AOFAS Annual Meeting

IARTIntegra LifeSciences2026-09-25 13:05 EST

Integra LifeSciences Marks 20 Years of CUSA® Technology with Liver Surgery Education at ACS Clinical Congress 2026

LEGNLegend Biotech Corporation2026-09-10 12:00 EST

Legend Biotech to Present Updated Long-Term and Real-World Evidence from CARVYKTI Clinical Program at the International Myeloma Society Annual Meeting

RVMDRevolution Medicines2026-09-02 21:50 EST

New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines’ RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer

RVMDRevolution Medicines2026-10-20 12:00 EST

Revolution Medicines Begins Treating Patients in Phase 3 RASolve 308 Trial Evaluating Zoldonrasib in Combination with Pembrolizumab and Chemotherapy as First-Line Treatment for Patients with Metastatic RAS G12D Non-Squamous Non-Small Cell Lung Cancer

View all latest news

Delcath Systems

Interventional Oncology Delcath Systems develops liver-directed therapies for primary and metastatic liver cancers. Its technology isolates hepatic circulation so high-dose chemotherapy can be delivered to the liver while limiting systemic exposure. HEPZATO KIT HEPZATO KIT combines melphalan with the company's percutaneous...

Recent company news

DCTHDelcath Systems2026-10-19 20:01 EST

Delcath Systems Highlights Clinical Program Presentations at ESMO Congress 2026 and Independent Data on Percutaneous Hepatic Perfusion in Liver-Dominant Metastatic Uveal Melanoma

DCTHDelcath Systems2026-09-11 20:01 EST

Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

DCTHDelcath Systems2026-08-31 20:01 EST

Delcath Systems to Participate in Upcoming Investor Conferences

DCTHDelcath Systems2026-08-06 12:01 EST

Delcath Systems Reports Second Quarter 2026 Results and Business Highlights

DCTHDelcath Systems2026-07-28 20:01 EST

Delcath Systems to Participate at the Canaccord Genuity 46th Annual Growth Conference

Stock data

Close
14.70 USD
Market cap
363.51M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States